1. The $69 billion CVS/Aetna merger will affect decision-making on employee healthcare benefits for 61% of 450 mid- to large-sized companies in the U.S., a new survey by benefits consultant Aon found. (Reuters)
2. Democratic lawmakers are pressuring the DEA to curb the supply of oxycodone, morphine, fentanyl, and other prescription painkillers. (Stat)
3. Allergan and Hungarian drugmaker Gedeon Richter reported positive Phase-III results for Vraylar in the treatment of adults with bipolar depression. The drug is already approved to treat schizophrenia. (Endpoints News)
4. As part of an ongoing patent dispute, Shire filed a motion for a preliminary injunction against Roche. Shire claims that Roche infringed on a key patent to develop haemophilia drug Hemlibra, which was approved by the FDA in November. (Reuters)
5. Novartis paid Ultragenyx $130 million for a priority review voucher. The drugmaker did not say how it plans to use the voucher, which is valid for a six-month review of a new drug application. (Endpoints News)
